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Non-melanoma skin cancers (NMSCs) are among the
most common human malignancies. Current methods
for their prevention include avoidance of natural and
artificial sources of UV radiation and using photopro-
tective clothing and sunscreens. However, these meth-
ods have proven to be inadequate in stemming the rise
in skin cancer incidence over the past several years.
There is accumulating evidence that cyclooxygenase-2
(COX-2), an enzyme involved in prostaglandin synth-
esis, may be involved in the pathogenesis of NMSC. In
preclinical studies, animals genetically deficient in the
COX-2 enzyme or that have been treated with phar-
macological inhibitors of COX-2 develop significantly
fewer tumors when subjected to a UV-induced skin
carcinogenesis protocol compared with control mice.
Several epidemiological studies in humans support the
concept that this enzyme is intimately involved in UV-
induced skin cancer development, and UV radiation is
known to augment COX-2 expression in human skin.
Recent studies suggest that drugs that block COX-2
expression may prevent the development of NMSCs.
Thus, pharmacologic agents that inhibit the enzyme
COX-2 may be effective chemopreventive agents for
NMSCs.
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Basal cell and squamous cell carcinomas (SCCs), grouped
together under the term non-melanoma skin cancer (NMSC),
are a major dermatologic problem. In the United States
alone, over 3.5 million new cases of this malignancy are
diagnosed each year (Rogers et al., 2010). This far exceeds
the 1.66 million cases of cancer in all other organs
combined (Siegel et al., 2013). In contrast to most other
malignancies in which the incidence has either stabilized or
begun to decline, the likelihood of developing an NMSC
continues to grow (Rogers et al., 2010). Moreover, NMSCs
are developing in younger and younger age groups; it is not
uncommon to see women in their 20s and 30s developing
their first NMSC (Christenson et al., 2005). The epidemic of
skin cancer represents a major public health issue and
places a tremendous cost burden on health-care systems in
the United States and around the world (Rogers and
Coldiron, 2013).
Because of the prevalence of the problem, there has been
considerable interest in developing methods by which skin
cancers can be prevented. The vast majority of skin cancers
are caused by overexposure to UV radiation from the sun and
from artificial light sources. Thus, much of the effort to prevent
skin cancer has centered on avoidance of excessive sun
exposure, education about the deleterious effects of artificial
tanning bed use, advice that outdoor activities should be
conducted as much as possible in shaded areas, and recom-
mendations that protective hats and long-sleeved clothing be
worn outside. However, the mainstay of skin cancer preven-
tion has focused on advising people to apply sunscreens
regularly. Although not denying the importance of these
topical agents, the few studies that have been conducted
evaluating their efficacy in skin cancer prevention have shown
only a modest reduction in actinic keratoses (AKs) (Thompson
et al., 1993) and SCCs of the skin (Green et al., 1999) and no
statistically significant reduction in the incidence of basal cell
carcinomas (BCCs) (Green et al., 1999). In addition, there is
inconsistent patient compliance with sunscreen use, even in
organ transplant recipients who are at greatest risk for UV-
induced NMSCs (Seukeran et al., 1998). Furthermore, large
amounts of sunscreen are required to achieve the full sunburn
protective factor value on the product label, and patients use
only about 25% of that amount when applying sunscreens
(Faurschou and Wulf, 2007). Finally, there is no effect of
sunscreens on prior UV damage to the skin. Thus, existing
methods are inadequate and additional measures are required
to retard the rising incidence of NMSC. Identification
and implementation of chemopreventive agents against
skin cancer represent one of the major unmet needs in
photodermatology.
CYCLOOXYGENASES AND CHEMOPREVENTION
There is strong evidence from experiments in animal models
and epidemiologic studies that cyclooxygenases are intimately
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involved in the promotion and progression stages of NMSCs,
and therefore may be excellent targets for the prevention of
NMSCs (Rundhaug and Fischer, 2008). There are two major
cyclooxygenase isoforms, cyclooxygenase-1 (COX-1) and
cyclooxygenase-2 (COX-2). COX-1 is constitutively expressed
in most cell types. COX-2 is not normally expressed in most
tissues but can be induced to do so by a variety of stimuli
including growth factors, cytokines, and tumor promoters
(Rundhaug and Fischer, 2008). UV radiation is a known
stimulus for COX-2 expression in the epidermis (see
Figure 1) (Buckman et al., 1998; Fischer et al., 1999; An
et al., 2002; Rodriguez-Burford et al., 2005). Cyclooxygenases
are prostaglandin-endoperoxide synthases that catalyze the
formation of prostaglandins from arachidonic acid (Brecher,
2002). UV-induced COX-2 expression increases prostaglan-
din E2 (PGE2), one of the major cyclooxygenase products
implicated in NMSC development. PGE2 binds to four
G-protein-coupled receptors, EP1–EP4, on the surface of cells,
including keratinocytes (Rundhaug et al., 2011). Each receptor
activates distinct signaling pathways, although there is
extensive cross talk between the pathways. EP1, EP2, and
EP4 have all been linked to UV-induced skin carcinogenesis in
animal models. PGE2 has been shown to increase tumor cell
proliferation, inhibit apoptosis, stimulate an inflammatory
response, promote immunosuppression, and facilitate tumor
invasion. All of these functional activities of PGE2 are
important contributors to the development of UV-induced
SCCs of the skin.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are med-
ications that are widely used in clinical practice for the
treatment of rheumatoid arthritis and osteoarthritis. These
agents act by inhibiting the action of the COX-1 and COX-2
enzymes and thus impair production of PGE2. NSAIDs have
been employed to investigate the role of cyclooxygenases in
disease (Ulrich et al., 2006; Fischer et al., 2011). Examples
of Food and Drug Administration-approved agents that
nonselectively inhibit both COX-1 and COX-2 include
sulindac, naproxen, and indomethacin. Celecoxib, on the
other hand, has a much greater effect on COX-2 than on
COX-1 (Kawamori et al., 1998). When used on a chronic
basis, COX-2 selective inhibitors have been associated with
adverse cardiovascular events, including heart attack and
stroke (Solomon et al., 2005; Kerr et al., 2007; Solomon
et al., 2008). Cardiovascular adverse events are also more
common with some, but not all, nonselective NSAIDs that
block both COX-1 and COX-2; naproxen may even have a
slight protective effect (Ray et al., 2002; Fosbol et al., 2009).
Other toxicities of NSAIDs include nausea, gastrointestinal
pain, and hemorrhage (Derry and Loke, 2000). Preclinical
data have shown that nitric oxide (NO)–releasing NSAIDs
such as NO-naproxen and NO-sulindac have much less
gastrointestinal toxicity compared with their non-NO–
releasing counterparts—i.e., naproxen and sulindac (Steele
et al., 2009; Blackler et al., 2012). Furthermore, NO–
releasing NSAIDs also augment the expression of antioxidant
response element genes, which may further augment their
chemopreventive activity.
ANIMAL MODELS
Convincing evidence to support the concept that cyclooxy-
genases have an essential role in UV-induced skin carcino-
genesis has been obtained from experiments in animal
models. In UV-induced skin tumorigenesis experiments in
which wild-type mice were compared with animals with a
heterozygous mutation in either the COX-1 or the COX-2
gene, COX-2-deficient mice had a significant reduction in
SCCs compared with wild-type mice, whereas those mice
with a deficiency in COX-1 were unaffected by the deficiency
and behaved exactly like wild-type mice (Fischer et al., 2007).
In contrast, both COX-1 and COX-2 appear to participate in
the development of BCCs. Ptchþ / mice are known to
develop large numbers of BCCs following exposure to UV
radiation (Tang et al., 2010). When mutations in the COX-1
and COX-2 genes were backcrossed onto this strain and those
mice were chronically exposed to UV irradiation, both COX-
1- and COX-2-deficient mice developed significantly fewer
BCCs compared with Ptchþ / mice without cyclooxygenase
deficiencies. The conclusion from these studies was that
COX-2, but not COX-1, is important for UV-induced SCCs,
whereas both COX-1 and COX-2 contribute to BCC
development. Thus, cyclooxygenase participation differs
depending on the type of malignancy. In other studies, it has
been shown that COX-1 diminishes apoptosis in UV-induced
SCCs but does not inhibit tumor cell proliferation or tumor
development (Pentland et al., 2004). Although it has not yet
been investigated, this may be different in animal models of
UV-induced BCC.
Experiments have also been conducted in animal models to
determine whether selective COX-2 inhibitors and nonselec-
tive COX-1 and COX-2 inhibitors might be effective chemo-
preventive agents for UV-induced NMSCs (Fischer et al.,
1999; Pentland et al., 1999; Rundhaug et al., 2007; Tang
et al., 2010). Those studies have shown that the COX-2














Figure 1. UV and cyclooxygenases. COX, cyclooxygenase; PGE2,
prostaglandin E2.
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in mice. The nonselective COX-1 and COX-2 inhibitors
naproxen, indomethacin, and sulindac and the NO–releasing
derivative NO-sulindac have also been observed to
dramatically reduce the number of UV-induced skin
tumors (M Athar, unpublished data; Chaudhary et al., 2013;
Mikulec et al., 2013).
Over the past several years, a number of natural and
dietary agents have been identified that are potent chemopre-
ventive agents for UV-induced skin cancers. Many of
these natural and dietary compounds contain polyphenols
that have a variety of different activities. Recent studies
have shown that some of these, such as grape seed proantho-
cyanidins, inhibit the expression of COX-2, and this effect is
associated with a reduction in the number of UV-induced skin
tumors in mice (Sharma and Katiyar, 2010).
MECHANISTIC STUDIES
The mechanism by which cyclooxygenases foster the
development of UV-induced skin cancers has been
investigated in detail, primarily by evaluating the parameters
that are affected by pharmacologic inhibition of these
enzymes.
It is known that PGE2 stimulates the proliferation of
malignant and premalignant keratinocytes (Ansari et al.
2008; Rundhaug et al. 2007). NSAIDs block this effect and
also promote apoptosis. Consistent with this observation,
sulindac is effective at attenuating the expression of several
markers of proliferation, including c-fos, cyclins D1 and A,
and proliferating cell nuclear antigen (Athar et al., 2004).
Similarly, the reduction in UV-induced tumor formation with
NO-sulindac is associated with an increase in the number of
TUNEL-positive cells, increased expression of pro-apoptotic
Bax, and decreased expression of anti-apoptotic Bcl-2
(Chaudhary et al., 2013). In UV-irradiated skin, there is an
increase in the phosphorylation of the mitogen-activated
protein kinase (MAP). extracellular signal–regulated
kinase1/2 (Erk 1/2), p38, and c-Jun N-terminal kinase1/2
(JNK 1/2), which are upstream signaling molecules of cellular
proliferation and inflammation. NO-sulindac blocks this
activity (Chaudhary et al., 2013).
COX-2 augments epithelial mesenchymal transition, the
process by which malignant cells weaken intercellular adhe-
sion and enhance motility, thus allowing them to penetrate
into surrounding tissues (Lee et al. 2008). NO-sulindac inhibits
epithelial mesenchymal transition to block the progression
of UVB-induced tumors by decreasing the expression of
mesenchymal markers fibronectin, N-cadherin, Snail, Slug,
and Twist and by increasing the epithelial cell polarity marker
E-cadherin (Chaudhary et al., 2013).
In addition to promoting the proliferation of pre-neoplastic
cells and facilitating epithelial mesenchymal transition, UV-
induced PGE2 production stimulates inflammation (Wilgus
et al., 2000), one consequence of which is to promote UV-
induced skin tumorigenesis (Wilgus et al., 2003). Topical
application of celecoxib or the EP1-specific inhibitor ONO-
87713 blocks both UV-induced inflammation and tumor
development (Wilgus et al., 2003; Tober et al., 2006).
In contrast to the nonspecific inflammatory response
that promotes UV-induced skin tumorigenesis, there is
an effective cell-mediated antitumor immune response that
inhibits UV-induced tumor development (Kripke, 1974). UV
radiation suppresses that response (Schwarz, 2008; Krutmann
et al., 2009; Gibbs and Norval, 2013). The nonselective COX-
1 and COX-2 inhibitor indomethacin abrogates the immuno-
suppressive effects of UV radiation (Chung et al., 1986;
Soontrapa et al., 2011). DNA hypermethylation has recently
been shown to be a mediator of UVB-induced immune
suppression and skin tumorigenesis (Prasad and Katiyar,
2013). The effects of UV radiation on DNA hypermethyla-
tion can be reversed by the cyclooxygenase inhibitors
indomethacin and celecoxib and by the EP2 antagonist
AH6809. These agents mediate this effect by reversing the
actions of PGE2 on DNA methyltransferase activity (Prasad
and Katiyar, 2013).
EPIDEMIOLOGIC STUDIES
A number of epidemiologic studies support the concept that
NSAIDs that inhibit cyclooxygenases have a positive effect in
decreasing the risk of cutaneous NMSC (Butler et al., 2005;
Grau et al., 2006; Clouser et al., 2009; Johannesdottir et al.,
2012). A case–control study based in Australia with a cohort
of 1,621 individuals captured NSAID use (Butler et al., 2005).
The incidence of SCCs and BCCs was self-reported by patients
and then confirmed by medical records. Participants were also
examined for AKs on the face, ears, right hand, and right
forearm (Butler et al., 2005). People who used NSAIDs more
than two times per week for at least a year had a statistically
significantly lower incidence of SCCs and lower AK counts
than those who had never used them or used them
infrequently. In another population-based case–control study
from Denmark, both NMSC and melanoma risks among
NSAID users were evaluated (Johannesdottir et al., 2012).
The incidence of BCCs, SCCs, and melanomas was identified
over a period of 18 years and compared with prescription
data of aspirin, nonselective NSAIDs, and selective COX-2
inhibitors. The use of aspirin, nonselective NSAIDs, and
COX-2 inhibitors was associated with decreased risk for
SCC and melanoma. Moreover, the reduction in risk
increased as the frequency and duration of NSAID use
increased. No association between NSAID use and BCC was
found.
Although several studies support the hypothesis that NSAIDs
suppress the development of UV-induced skin cancers, other
reports have not found a significant association between
NSAIDs and skin cancer prevention or have found the
results to be inconclusive (Grau et al., 2006; Asgari et al.,
2010; Nunes et al., 2011). A retrospective case–control study
assessing the association between NSAIDs and SCCs
examined self-reported NSAID use in 415 patients with
histopathologically confirmed SCC (Asgari et al., 2010).
Study questionnaires collected information on over-the-
counter and prescription NSAID use during the 10 years
prior to SCC diagnosis. The results from this study showed
no decrease in the incidence of SCCs from NSAID use
regardless of dose or duration. Another study examined data
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from the Skin Cancer Chemoprevention Study for an
association between NSAID use and the risk for BCCs and
SCCs. No significant protective effect of NSAIDs on BCCs was
observed (Grau et al., 2006). Overall rates of SCC incidence
were lower for NSAID users, although this may have been due
to a chance association.
TRANSLATIONAL STUDIES
The consequences of UV radiation on cyclooxygenase
expression in animal models are similar to those seen in
humans. When the skin of normal volunteers is exposed
to a single dose of UV radiation from a solar simulator that
is 1–2 times the minimal erythema dose, a substantial
increase in COX-2 expression occurs, but there is no change
in COX-1 expression (Buckman et al., 1998). In some
individuals, this can be suppressed by pretreatment with
celecoxib (Rodriguez-Burford et al., 2005). Moreover,
immunohistological studies have shown that, whereas
COX-2 is not found in normal skin, it is present in AKs and
SCCs (An et al., 2002). COX-2 is also expressed in the
parenchyma and/or the stroma surrounding BCCs (An et al.,
2002; Tang et al., 2010).
Because of the abundance of data from animal experiments,
epidemiologic studies suggesting that NSAIDs may suppress
the development of UV-induced tumors, and the findings that
NSAIDs exert a protective effect in colon chemoprevention
trials (Meyskens et al., 2008), two clinical studies have been
conducted to determine whether COX-2 inhibitors might be
effective preventive agents for NMSCs (Elmets et al., 2010;
Tang et al., 2010). One of these was a double-blind, placebo-
controlled trial conducted at eight U.S. academic centers
(Elmets et al., 2010). Two hundred and forty subjects with
Fitzpatrick, sun-reactive skin types I–III who had 10–40 AKs at
baseline and a prior histological diagnosis of at least one AK or
NMSC were randomized to receive celecoxib (200 mg b.i.d.),
an oral selective inhibitor of COX-2 that is Food and Drug
Administration approved for the treatment of rheumatoid
arthritis, osteoarthritis, and the adjunct treatment of familial
adenomatous polyposis, or placebo. A known photosensitivity
disorder, use of topical medications other than sunscreens or
emollients, recent treatment for AKs and NSAID use other than
cardioprotective doses of aspirin were the exclusion criteria.
Participants who enrolled in the study were primarily male.
The mean age was 65 years, and all had extensive actinic
damage. The mean number of NMSCs prior to entry into the
study was 2.3, and the mean number of AKs at baseline was
22.4. Participants were placed on celecoxib or placebo for 9
months and were followed up for an additional 2 months off
medication.
There was no effect of celecoxib on the incidence of AKs.
However, there was a dramatic decrease in the incidence of
NMSCs. At 11 months, there was a 58% reduction in NMSCs.
The difference between the celecoxib- and placebo-treated
groups first became apparent 3 months after initiation of
therapy and became statistically significant at 9 months. There
was no rebound in the incidence of skin cancer in the 2
months after completion of celecoxib treatment, although it
should be noted that the 2-month duration was relatively
short. When BCCs and SCCs were analyzed separately,
celecoxib was observed to be protective for both. There was
no significant difference in serious adverse events or cardio-
vascular adverse events between the two groups. However, it
should be noted that the major cardiovascular toxicity from
COX-2 inhibitors occurs after 12–18 months, and hence the
absence of side effects after 9 months would be expected
(Solomon et al., 2005).
Studies examining the chemopreventive effects of celecoxib
have also been conducted in patients with basal cell nevus
syndrome (Tang et al., 2010). Sixty basal cell nevus syndrome
patients were enrolled in a trial in which they received
celecoxib or placebo for 2 years. In those individuals who
had less than 15 BCCs at the initiation of study, the increase in
new BCCs was only 22% compared with 48% in those who
received placebo. The difference between the two groups was
statistically significant.
From these studies, it is reasonable to conclude the follow-
ing: (1) inhibition of COX-2 is an effective means of limiting
the development of cutaneous squamous cell and BCCs; (2)
COX-2 acts at a late stage in skin tumor development based
on the fact that AKs were not prevented by celecoxib
treatment; and (3) celecoxib works rapidly and is highly
effective.
The preclinical, epidemiologic, and translational studies
provide proof of principle that agents that inhibit COX-2 have
the potential to limit the development of new NMSCs. Patients
with extensive actinic damage often develop both BCC and
SCC. A particularly attractive feature of NSAIDs and other
agents that block COX-2 is their potential to block both types
of NMSC. Whether alternatives to celecoxib, which include
nonspecific COX-1 and COX-2 inhibitors such as naproxen or
sulindac, topical application of cyclooxygenase inhibitors, or
dietary chemopreventive agents that limit COX-2 activities
can be employed on a long-term basis to stem the increase in
NMSCs remains to be determined.
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